Drugs / SXC-2023
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06343532 | Oct → Dec 2024 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT03542435 | Apr → Aug 2018 | — | Promentis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03301298 | Sep 2017 → Feb 2018 | — | Promentis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03887429 | Mar → Jul 2019 | impulse control disorder | Promentis Pharmaceuticals, Inc. | Completed | Mixed |
| Phase 2 | NCT03797521 | Dec 2018 → Dec 2019 | trichotillomania | Promentis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-10-31 | Promentis Pharmaceuticals, Inc. | Results Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study promentispharma.com ↗
The study reveals a clear effect associated with SXC-2023 administration in measures of impulse control closely related to trichotillomania and other indications of interest to the Company, and reinforces the attractive safety profile of SXC-2023. |
| 2018-11-16 | Promentis Pharmaceuticals, Inc. | Results Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism promentispharma.com ↗
SXC-2023 proved to be safe and well-tolerated over a wide dose range in healthy volunteers in both the SAD and MAD studies, and demonstrated a very consistent PK profile. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-10-31 | Promentis Pharmaceuticals, Inc. | Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study promentispharma.com ↗ |
| 2019-01-17 | Promentis Pharmaceuticals, Inc. | Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism promentispharma.com ↗ |
| 2018-11-16 | Promentis Pharmaceuticals, Inc. | Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism promentispharma.com ↗ |
| 2017-11-20 | Promentis Pharmaceuticals, Inc. | Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders promentispharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SXC-2023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03797521 ↗ |
| Route | Oral | “Single dose of 50 mg, given orally in capsule form.” NCT03301298 ↗ |